Dechra Pharmaceuticals Croissance future

Future contrôle des critères 4/6

Dechra Pharmaceuticals devrait augmenter ses bénéfices et son chiffre d'affaires de 62.5% et de 7.9% par an respectivement. Le BPA devrait croître de de 89.8% par an. Le rendement des capitaux propres devrait être 19.8% dans 3 ans.

Informations clés

62.5%

Taux de croissance des bénéfices

89.8%

Taux de croissance du BPA

Pharmaceuticals croissance des bénéfices	19.6%
Taux de croissance des recettes	7.9%
Rendement futur des capitaux propres	19.8%
Couverture par les analystes	Low
Dernière mise à jour	03 Jan 2024

Mises à jour récentes de la croissance future

Pas de mise à jour

Recent updates

Prévisions de croissance des bénéfices et des revenus

BATS-CHIXE:DPHL - Estimations futures des analystes et données financières antérieures (GBP Millions )
Date	Recettes	Les revenus	Flux de trésorerie disponible	Cash from Op	Moy. Nombre d'analystes
6/30/2026	954	187	N/A	N/A	1
6/30/2025	904	123	160	182	5
6/30/2024	837	102	142	163	2
6/30/2023	762	-28	33	64	N/A
3/31/2023	744	6	39	75	N/A
12/31/2022	727	40	45	86	N/A
9/30/2022	704	49	45	105	N/A
6/30/2022	682	58	45	123	N/A
3/31/2022	661	66	48	121	N/A
12/31/2021	641	73	51	119	N/A
9/30/2021	624	64	3	104	N/A
6/30/2021	608	56	-45	89	N/A
3/31/2021	587	50	-45	102	N/A
12/31/2020	566	44	-44	114	N/A
9/30/2020	541	39	7	110	N/A
6/30/2020	515	34	57	106	N/A
3/31/2020	507	31	57	91	N/A
12/31/2019	499	29	57	76	N/A
9/30/2019	490	30	58	79	N/A
6/30/2019	482	31	59	82	N/A
3/31/2019	463	28	61	82	N/A
12/31/2018	444	25	62	81	N/A
9/30/2018	426	30	57	73	N/A
6/30/2018	407	36	51	64	N/A
3/31/2018	394	40	57	69	N/A
12/31/2017	381	43	63	75	N/A
9/30/2017	370	35	65	76	N/A
6/30/2017	359	26	67	77	N/A
3/31/2017	334	19	N/A	69	N/A
12/31/2016	309	11	N/A	62	N/A
9/30/2016	278	12	N/A	53	N/A
6/30/2016	248	13	N/A	44	N/A
3/31/2016	230	17	N/A	43	N/A
12/31/2015	213	20	N/A	42	N/A
9/30/2015	208	20	N/A	42	N/A
6/30/2015	203	19	N/A	41	N/A
3/31/2015	201	21	N/A	41	N/A
12/31/2014	199	22	N/A	42	N/A
9/30/2014	196	21	N/A	27	N/A
6/30/2014	194	19	N/A	11	N/A
12/31/2013	193	14	N/A	25	N/A
9/30/2013	191	13	N/A	31	N/A
6/30/2013	189	11	N/A	37	N/A

Prévisions de croissance des analystes

Taux de revenus par rapport au taux d'épargne: DPHL devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance plus rapide que le taux d'épargne ( 1.5% ).

Bénéfices vs marché: DPHL devrait devenir rentable au cours des 3 prochaines années, ce qui est considéré comme une croissance supérieure à la moyenne du marché.

Croissance élevée des bénéfices: DPHL devrait devenir rentable dans les 3 prochaines années.

Chiffre d'affaires vs marché: Le chiffre d'affaires de DPHL ( 7.9% par an) devrait croître plus rapidement que le marché UK ( 3.5% par an).

Croissance élevée des revenus: Le chiffre d'affaires de DPHL ( 7.9% par an) devrait croître plus lentement que 20% par an.

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

ROE futur: Le retour sur capitaux propres de DPHL devrait être faible dans 3 ans ( 19.8 %).

Dechra Pharmaceuticals Croissance future

Future contrôle des critères 4/6

Informations clés

Mises à jour récentes de la croissance future

Recent updates

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited agreed to acquire Invetx, Inc. from a group of shareholders for $520 million.

Dechra Pharmaceuticals Limited reached agreement in principle to acquire 33.34% stake in STEM Animal Health Inc. for $4.7 million.

Dechra Group Holdings Limited Announces Resignation of Sara Huda as Director

EQT X EUR SCSp and EQT X USD SCSp managed by Eqt Fund Management S.à R.L. and Luxinva SA (the Offerors) completed the acquisition of Dechra Pharmaceuticals PLC (LSE:DPH).

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE All-Share Index (GBP)

Dechra Pharmaceuticals' Cancellation of Listing and Admission to Trading of Shares Expected on 17 January 2024

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals Plc Announces Directorate Change

Dechra Pharmaceuticals PLC to Report Fiscal Year 2023 Results on Oct 12, 2023

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Dechra Pharmaceuticals plc Announces Resignation of Ishbel Macpherson as Non-Executive Director

Dechra Pharmaceuticals Intends to Delist from Official List

First half 2023 earnings released: EPS: UK£0.20 (vs UK£0.38 in 1H 2022)

Investor sentiment improved over the past week

Dechra Pharmaceuticals PLC Appoints Geeta Gopalan as A Non-Executive Director of the Company

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 100 Index

Now 21% undervalued after recent price drop

Less than half of directors are independent

Upcoming dividend of UK£0.33 per share

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 19, 2023

Full year 2022 earnings released: EPS: UK£0.54 (vs UK£0.51 in FY 2021)

Dechra Pharmaceuticals plc Proposes Final Dividend for the Year Ended June 30, 2022

Dechra Pharmaceuticals PLC (LSE:DPH) acquired Med-Pharmex, Inc. from DW Management Services, LLC for $260 million on a debt-free and cash-free basis.

Dechra Pharmaceuticals PLC (LSE : DPH) agreed to acquire Piedmont Animal Health LLC for approximately $210 million.

Now 21% undervalued after recent price drop

Dechra Pharmaceuticals PLC Announces Executive Changes

Less than half of directors are independent

Non-Executive Chairman recently bought UK£99k worth of stock

Upcoming dividend of UK£0.12 per share

First half 2022 earnings: Revenues and EPS in line with analyst expectations

Dechra Pharmaceuticals PLC Declares Interim Dividend, Payable on April 7, 2022

Dechra Pharmaceuticals plc Announces Executive Changes

Dechra Pharmaceuticals PLC (LSE:DPH) agreed to acquire Worldwide Rights to Verdinexor from Anivive Lifesciences, Inc.

Dechra Pharmaceuticals PLC(LSE:DPH) dropped from FTSE 250 (Ex Investment Companies) Index (GBP)

Non-Executive Director Denise Goode has left the company

Upcoming dividend of UK£0.29 per share

Board Member recently sold UK£875k worth of stock

Full year 2021 earnings released: EPS UK£0.51 (vs UK£0.33 in FY 2020)

Board Member recently sold UK£963k worth of stock

First half 2021 earnings released: EPS UK£0.22 (vs UK£0.13 in 1H 2020)

Akston Biosciences Signs Licensing Agreement with Dechra Pharma for Aks-425C

New 90-day high: UK£37.50

Dechra Pharmaceuticals PLC, Annual General Meeting, Oct 21, 2021

New 90-day high: UK£35.98

Dechra Pharmaceuticals PLC Launches Mirataz

Dechra Pharmaceuticals PLC to Report First Half, 2021 Results on Feb 22, 2021

Prévisions de croissance des bénéfices et des revenus

Prévisions de croissance des analystes

Prévisions de croissance du bénéfice par action

Rendement futur des capitaux propres

Découvrir les entreprises en croissance